Biomedical
Seminal papers in urology: two-year outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for refractory urgency urinary incontinence: a Randomized Trial
Peer Reviewed
Abstract
Key Questions about Refractory Urgency Urinary Incontinence Treatments
The article "Seminal papers in urology: two-year outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for refractory urgency urinary incontinence: a Randomized Trial" critically reviews the study "Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial." This original study, published in 2018, was a multi-center, open-label, parallel randomized trial that allocated females 1:1 to receive Sacral Neuromodulation (SNM) or OnabotulinumtoxinA (BTX) 200 units. The primary outcome was the change in mean daily urinary urgency incontinence episodes (UUIE) over 24 months. The study did not demonstrate a significant difference between treatments (-3.88 vs. -3.50 episodes per day). However, women treated with BTX were more satisfied but reported higher rates of urinary tract infections (UTIs). The two treatments provide comparable third-line treatment options for patients with refractory urgency urinary incontinence.
1. What was the primary outcome of the original study comparing SNM and BTX?
The primary outcome was the change in mean daily urinary urgency incontinence episodes (UUIE) over 24 months. The study found no significant difference between the two treatments in this regard.
2. What were the secondary findings regarding patient satisfaction and adverse events?
Women treated with BTX reported higher satisfaction levels compared to those treated with SNM. However, the BTX group also experienced higher rates of urinary tract infections (UTIs).
3. What is the significance of these findings for clinical practice?
The findings suggest that both SNM and BTX are viable third-line treatment options for patients with refractory urgency urinary incontinence. The choice between the two may depend on individual patient factors, including treatment preferences and tolerance to potential adverse events.
